We therefore postulate that because IL-6, MMP-9, TNF-α and hs-CRP levels in AIS patients with high blood glucose variability who are treated with intravenous alteplase thrombolysis are significantly increased, the degree of inflammation is severe, which may lead to poor prognoses. The gene discussed is MMP9; the disease is androgen insensitivity syndrome.